<DOC>
	<DOCNO>NCT00192608</DOCNO>
	<brief_summary>Saquinavir Atazanavir drug use combination therapy treat HIV disease . Saquinavir currently available 200 milligram capsule . Most individual currently saquinavir require take 5 tablet twice day . In attempt reduce number pill , new capsule develop contain 500 milligram saquinavir . This study ass : ) blood drug level individual take saquinavir formulation , ii ) blood drug level individual take saquinavir formulation give atazanavir , iii ) 48 week follow individual receive new saquinavir formulation atazanavir HIV therapy .</brief_summary>
	<brief_title>A 48-Week , Randomised , Study Describe Pharmacokinetic Profile Durability Atazanavir-Saquinavir-Ritonavir Once Daily Describe Pharmacokinetic Profile Saquinavir-Ritonavir Using Saquinavir 500mg Formulation : ASK-500 Study</brief_title>
	<detailed_description>BACKGROUND The development anti-HIV therapy treatment HIV disease improve quality life survival many people HIV . However treatment always work long period , medication often difficult take due side effect large number pill take . This lead researcher look new way treat HIV medication require few number pill few side effect . Atazanavir saquinavir two drug use treat HIV come class drug know protease inhibitor . Atazanavir advantage take day . Saquinavir available new formulation ( type pill ) , require few number pill take daily . AIM The purpose study investigate use two drug use together ritonavir daily HIV treatment , consist 6 tablet . Furthermore study look blood drug level individual atazanavir , saquinavir ritonavir without new saquinavir formulation ensure blood level drug adequate . For individual currently old saquinavir formulation , study also look blood drug level change new formulation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>HIV1 infected individual age 18 year On stable antiretroviral therapy least three month consist nucleoside reverse transcriptase inhibitor protease inhibitor OR On stable antiretroviral therapy least three month consist atazanavirsaquinavirritonavir Undetectable HIV RNA viral load past three month Individuals receive nonnucleoside reverse transcriptase inhibitor within past three month Individuals currently receive enzyme induce agent ( per Individuals receive ritonavir dos great 100 mg bid Active AIDS defining illnesses Previously document intolerance virological failure saquinavir Previously document intolerance virological failure atazanavir Patients coinfected Hepatitis B likely require , clinician 's opinion , HBV nucleoside therapy study . Female patient pregnant , breastfeeding , plan become pregnant study Any current clinical laboratory parameter ACTG Grade 4 ( except lipid &amp; CK ) Evidence ongoing alcohol and/or drug substance abuse would result patient unreliable fulfilling condition protocol Prior nonadherence antiretroviral treatment regimen would result patient unreliable fulfilling condition protocol Evidence active opportunistic infection , intercurrent illness , drug toxicity condition would preclude patient take prescribed antiretroviral regimen Conditions might interfere evaluation disease study . Conditions/allergies may compromise safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Pharmacokinetics , atazanavir , saquinavir , ritonavir , HIV</keyword>
</DOC>